Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Satisfactory Clinical Outcomes and Continuance of Sports After Hip Arthroscopic Labral Repair in Young Competitive Athletes at Minimum 8.5‐Year Follow‐Up
Lamba, Abhinav , Wang, Allen S. , Okoroha, Kelechi R. , Levy, Bruce A. , Krych, Aaron J. , Hevesi, Mario , Krych, Aaron J , Wang, Allen , Lamba, Abhinav , Hevesi, Mario

Mayo Clinic

Arthroscopy | September 15, 2023 | Volume: 40 | Issue: 4 | Pages: 1126-1132

10.1016/j.arthro.2023.08.082 | PMID 37716632 Get It

Purpose To evaluate long‐term patient‐reported outcomes and achievement rates of patient acceptable symptomatic state (PASS) in young athletes undergoing hip arthroscopy, and to report long‐term sports continuance and reoperation. Methods Inclusion criteria consisted of age <24 years at surgery, femoroacetabular impingement undergoing primary hip arthroscopy with labral repair, and participation in sport with intent to return to sport after surgery. The enrollment period was from April 2009 to June 2014. Modified Harris Hip Scores (mHHS), Hip Outcome Score (HOS), HOS Activities of Daily Living (HOS‐ADL), and HOS Sport (HOS‐Sport) were collected preoperatively, 2 years’ postoperatively, and final follow‐up. Patients were evaluated for PASS achievement, reoperation, and sports participation. Results Forty‐two hips in 37 patients (11 male, 26 female, age: 17.7 ± 2.1 years, range 13.6‐23.0, body mass index 22.8 ± 2.9, range 17.6‐33.7) met inclusion criteria and were followed for 10.0 ± 1.3 years (range 8.5‐13.0) postoperatively. Mean mHHS, HOS‐ADL and HOS‐Sports outcome scores at minimum 8.5 years were 82.2 ± 12.9, 89.6 ± 10.9, and 81.8 ± 16.4, respectively, with significant ( P < .001) postoperative improvements. Thirty survey respondents (83%) met PASS for mHHS, 27 (75%) for HOS‐ADL, and 24 (67%) for HOS‐Sports. At minimum 8.5‐year follow‐up, only 9 of 37 (24%) cited their hip as the reason for stopping sport. Of the remaining patients, 17 of 28 (61%), continued playing their initial sport. There was no difference in patient‐reported outcomes between patients who endorsed sports continuance and patients who did not report sports continuance and did not cite their hip as a reason ( P ≥ .229). At final follow‐up, 4 hips (10%) had undergone subsequent surgical intervention at a mean of 4.8 ± 3.3 years (range 1.0‐8.4) postoperatively. Conclusions Durable mid‐term outcomes and satisfactory PASS achievement rates are observed in young amateur athletes undergoing primary hip arthroscopy. At minimum 8.5‐year follow up, approximately 1 in 4 patients discontinue their sports due to hip related reasons. Level of Evidence Level IV, case‐series.
A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2
Zanti, Maria , O'Mahony, Denise G , Li, Hongyan , Aittomäkkiki, Kristiina, Andrulis, Irene L. , Aronson, Kristan J. , Bolla, Manjeet K. , Brenner, Hermann , Caputo, Sandrine M. , Chang‐Claude, Jenny , Collaborators, GC-HBOC study, Daly, Mary B., Nicolo, Arcangela De , Eccles, Diana M., Engel, Christoph , Evans, D. Gareth , Fasching, Peter A. , Giele, Willemina R. R. Geurts -, Glendon, Gord , Goldberg, Mark S. , Gómez, E. , Güendert, Melanie, Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harkness, Elaine F. , Hogervorst, Frans B.L., Hoppe, Reiner , Houdayer, Claude , Houlston, Richard S. , Howell, Anthony , Investigators, ABCTB, Jakimovska, Milena , John, Esther M. , Kristensen, Vessela N. , Lambrechts, Diether , Léone, Mélanie, Lindblom, Annika , Mannermaa, Arto, Manoochehri, Mehdi, Manoukian, Siranoush , Menon, Usha , Offit, Kenneth, Park, Sue K. , Peto, Julian , Plaseska‐Karanfilska, Dijana , Romero, Atocha , Schmutzler, Rita K. , Stone, Jennifer , Tapper, William , Teo, Soo‐Hwang , Thomassen, Mads , Vachon, Celine M. , Vega, Ana , Wang, Qin , Wappenschmidt, Barbara , Zheng, Wei , Easton, Douglas F. , Goldgar, David E., Eccles, Diana , Lambrechts, Diether , Houdayer, Claude , Lambrechts, Diether , Teo, Soo H , Eccles, Diana , Menon, Usha , Houlston, Richard S , Vega, Ana , Evans, D Gareth , John, Esther M , Lambrechts, Diether , Brenner, Hermann , Romero, Atocha , Engel, Christoph , Zheng, Wei , Stone, Jennifer , Gómez-García, Encarna B , De Nicolo, Arcangela , Manoukian, Siranoush , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Parsons, Michael T. , Dennis, Joe , Anton‐Culver, Hoda , Augustinsson, Annelie , Becher, Heiko , Bojesen, Stig E. , Brown, Melissa A. , Buys, Saundra S. , Canzian, Federico , Castelao, Jose E. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , Gago-Domínguez, Manuela , García‐Closas, Montserrat , García-Sáenz, José Á. , Gentry‐Maharaj, Aleksandra , Geurts-Giele, Willemina R.R. , Giles, Graham G. , Guénel, Pascal , Hall, Per N , Hollestelle, Antoinette , Hopper, John L. , Jakubowska, Anna , Jernström, Helena , Kaaks, Rudolf , Kitahara, Cari M. , Koutros, Stella , Kraft, Peter , Lacey, James V. , Léoné, Mélanie, Lubiński, Jan , Lush, Michael J. , Mannermaa, Arto, Margolin, Sara , Martı́nez, Marı́a Elena , Milne, Roger L. , Monteiro, Álvaro N.A. , Murphy, Rachel A. , Neuhausen, Susan L. , Nevanlinna, Heli , Newman, William G. , James, Paul A. , Peterlongo, Paolo , Punie, Kevin , Radice, Paolo , Rashid, Muhammad Usman , Rennert, Gad , Rosenberg, Efraim H. , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Shu, Xiao‐Ou , Simard, Jacques , Southey, Melissa C. , Stoppa‐Lyonnet, Dominique , Tamimi, Rulla M. , Taylor, Jack A. , Teras, Lauren R. , Terry, Mary Beth , Troester, Melissa A. , Vachon, Celine M. , Vreeswijk, Maaike P.G. , Weinberg, Clarice R. , Wolk, Alicja , Feng, Bing , Couch, Fergus J. , Spurdle, Amanda B. , Michailidou, Kyriaki

Mayo Clinic

Human Mutation | September 15, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-17

10.1155/2023/9961341 | PMID 38725546 Get It

A large number of variants identified through clinical genetic testing in disease susceptibility genes are of uncertain significance (VUS). Following the recommendations of the American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP), the frequency in case-control datasets (PS4 criterion) can inform their interpretation. We present a novel case-control likelihood ratio-based method that incorporates gene-specific age-related penetrance. We demonstrate the utility of this method in the analysis of simulated and real datasets. In the analysis of simulated data, the likelihood ratio method was more powerful compared to other methods. Likelihood ratios were calculated for a case-control dataset of BRCA1 and BRCA2 variants from the Breast Cancer Association Consortium (BCAC) and compared with logistic regression results. A larger number of variants reached evidence in favor of pathogenicity, and a substantial number of variants had evidence against pathogenicity—findings that would not have been reached using other case-control analysis methods. Our novel method provides greater power to classify rare variants compared with classical case-control methods. As an initiative from the ENIGMA Analytical Working Group, we provide user-friendly scripts and preformatted Excel calculators for implementation of the method for rare variants in BRCA1, BRCA2, and other high-risk genes with known penetrance.
Clinical Outcomes Following Bifurcation Techniques for Percutaneous Coronary Intervention
Krittanawong, Chayakrit , Qadeer, Yusuf Kamran , Irshad, Umer, Wang, Zhen , Sharma, Samin K. , Virk, Hafeez Ul Hassan , Alam, Mahboob

Mayo Clinic

Journal of Clinical Medicine | September 12, 2023 | Volume: 12 | Issue: 18 | Pages: 5916

10.3390/jcm12185916 | PMID 37762857 Get It

Bifurcation lesions account for 20% of all percutaneous coronary interventions and represent a complex subset which are associated with lower procedural success and higher rates of restenosis [...]
Causally interpretable meta‐analysis: Clearly defined causal effects and two case studies
Rott, Kollin W. , Brønfort, Gert , Chu, Haitao , Huling, Jared D. , Leininger, Brent, Murad, Mohammad Hassan, Chu, Haitao , Murad, M. Hassan , Wang, Zhen , Hodges, James S.

Mayo Clinic

Research Synthesis Methods | September 12, 2023 | Volume: 15 | Issue: 1 | Pages: 61-72

10.1002/jrsm.1671 | PMID 37696604 Get It

AbstractMeta‐analysis is commonly used to combine results from multiple clinical trials, but traditional meta‐analysis methods do not refer explicitly to a population of individuals to whom the results apply and it is not clear how to use their results to assess a treatment's effect for a population of interest. We describe recently‐introduced causally interpretable meta‐analysis methods and apply their treatment effect estimators to two individual‐participant data sets. These estimators transport estimated treatment effects from studies in the meta‐analysis to a specified target population using the individuals' potentially effect‐modifying covariates. We consider different regression and weighting methods within this approach and compare the results to traditional aggregated‐data meta‐analysis methods. In our applications, certain versions of the causally interpretable methods performed somewhat better than the traditional methods, but the latter generally did well. The causally interpretable methods offer the most promise when covariates modify treatment effects and our results suggest that traditional methods work well when there is little effect heterogeneity. The causally interpretable approach gives meta‐analysis an appealing theoretical framework by relating an estimator directly to a specific population and lays a solid foundation for future developments.
Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry
Hum, Ryan Malcolm , Lamb, Janine A. , Oldroyd, Alexander , Wang, Guochun , Wedderburn, Lucy R, Diederichsen, Louise Pyndt , Schmidt, Jens , Danieli, Maria Giovanna , Oakley, Paula, Griger, Zoltán , Phuong, Thuy Nguyen Thi , Kodishala, Chanakya , Mercado, Mónica Vázquez-Del , Andersson, Helena , Paepe, Boél De , Maurer, Britta , McCann, Liza , Pipitone, Nicolò , McHugh, Neil , New, Robert P, Ollier, William , Krogh, Niels Steen , Lundberg, Ingrid E. , Chinoy, Hector , Registry, MYONET, D’hose, Sophie, Lu, Xin , Tian, Xiaolan , Pleštilová, Lenka, Barochová, Tereza, Kubínová, Kateřina , Gelardi, Chiara, Paladini, Alberto , Piga, Mario Andrea , Jara, Luis J. , Cruz‐Reyes, Claudia , Andrade-Ortega, Lilia, Medrano-Ramírez, Gabriel , Salazar-Páramo, Mario , Chavarría-Ávila, Efrain , Aguilar-Vázquez, Andrea, Anda, Jesús-Aureliano Robles-De , Molberg, Øyvind , Dastmalchi, Maryam, Notarnicola, Antonella , Gheorghe, Karina, Liden, Maria, Hanna, Balsam , Jalal, Awat, Hellström, Helena, Martineus, Jehns Christian, New, Paul, Platt, Hazel, Ahmed, Yasmeen , Armstrong, Raymond, Bernstein, Robert, Black, Carol M., Butler, Robin, Carty, John , Chattopadhyay, Chandra, Chelliah, E G, Clarke, Fiona, Dawes, P. T., Devlin, Joseph, Edwards, Christopher, Emery, Paul , Fordham, J. L. A., Fraser, Alexander, Gaston, Hill, Gordon, Patrick , Griffiths, Bridget , Gunawardena, Harsha , Hall, Frances, Hanna, Michael G. , Harrison, Beverley, Hay, Elaine M. , Hilton‐Jones, David, Horden, Lesley, Jones, Adrian, Kamath, Sanjeet, Kennedy, Thomas J. , Klimiuk, P S, Knights, Sally, Lambert, John, Laxminarayan, Ramasharan, Lecky, Bryan, Marks, Jeffrey M., Martin, Michael F., McGonagle, Dennis , McHugh, Neil, McKenna, Francis, McLaren, John, McMahon, Michael , McRorie, Euan , Merry, P, Miller, James , Nicholls, Anne, Ong, Voon , Over, K. E., Packham, John, Pipitone, Nicolo, Plant, Michael, Pountain, G., Pullar, T, Roberts, Mark, Scott, David A. , Shadforth, M F, Sheeran, Thomas, Srinivasan, Arul, Swinson, David, Teh, Lee‐Suan , Webley, M, Winer, Jonathan M., Wedderburn, Lucy R. , Lilleker, James B , Lamb, Janine A , Oldroyd, Alexander G S , Wedderburn, Lucy R , Griger, Zoltan , Nguyen Thi Phuong, Thuy , Kodishala, Chanakya , Vazquez-Del Mercado, Monica , De Paepe, Boel , McHugh, Neil , Vencovsky, Jiri , Lundberg, Ingrid E , Chinoy, Hector , McCann, Liza J , Bleecker, Jan De , Vencovský, Jiří , Registry, MYONET, Mann, H. , Kryštůfková, Olga , Klein, Martin , Saavedra, Miguel A , Lastra, Olga Lidia Vera , Satoh, Minoru , Petri, Marcelo H. , Rönnelid, Johan , Lan, Nguyễn Thị Ngọc , Padyukov, Leonid , Rothwell, Simon W. , Bernstein, Robert, Bowman, Simon , Bruce, Ian N , Carty, John, Denton, Christopher P. , Edwards, Christopher, Fordham, John, Isaacs, John Dudley , Isenberg, David , Kitas, George D. , Lanyon, Peter , Luqmani, Raashid Ahmed , Machado, Pedro , Marks, Jeffrey, Martin, Michael, McHugh, Neil, Miles, Sarah, Nixon, Jennifer, Ong, Voon, Packham, John, Pipitone, Nicolo, Sanders, Paul W. , Williams, Brian, Winer, Jonathan

Mayo Clinic

Rheumatology | September 11, 2023 | Volume: 63 | Issue: 8 | Pages: 2093-2100

10.1093/rheumatology/kead481 | PMID 37698987 Get It

Abstract Objectives To compare clinical characteristics, including the frequency of cutaneous, extramuscular manifestations and malignancy, between adults with anti-synthetase syndrome (ASyS) and DM. Methods Using data regarding adults from the MYONET registry, a cohort of DM patients with anti-Mi2/-TIF1γ/-NXP2/-SAE/-MDA5 autoantibodies, and a cohort of ASyS patients with anti-tRNA synthetase autoantibodies (anti-Jo1/-PL7/-PL12/-OJ/-EJ/-Zo/-KS) were identified. Patients with DM sine dermatitis or with discordant dual autoantibody specificities were excluded. Sub-cohorts of patients with ASyS with or without skin involvement were defined based on presence of DM-type rashes (heliotrope rash, Gottron’s papules/sign, violaceous rash, shawl sign, V-sign, erythroderma, and/or periorbital rash). Results In total 1054 patients were included (DM, n = 405; ASyS, n = 649). In the ASyS cohort, 31% (n = 203) had DM-type skin involvement (ASyS-DMskin). A higher frequency of extramuscular manifestations, including Mechanic’s hands, Raynaud’s phenomenon, arthritis, interstitial lung disease and cardiac involvement differentiated ASyS-DMskin from DM (all P &lt; 0.001), whereas higher frequency of any of four DM-type rashes—heliotrope rash (n = 248, 61% vs n = 90, 44%), violaceous rash (n = 166, 41% vs n = 57, 9%), V-sign (n = 124, 31% vs n = 28, 4%), and shawl sign (n = 133, 33% vs n = 18, 3%)—differentiated DM from ASyS-DMskin (all P &lt; 0.005). Cancer-associated myositis (CAM) was more frequent in DM (n = 67, 17%) compared with ASyS (n = 21, 3%) and ASyS-DMskin (n = 7, 3%) cohorts (both P &lt; 0.001). Conclusion DM-type rashes are frequent in patients with ASyS; however, distinct clinical manifestations differentiate these patients from classical DM. Skin involvement in ASyS does not necessitate increased malignancy surveillance. These findings will inform future ASyS classification criteria and patient management.
P14.07.B CELL-FREE DNA IN LONGITUDINALLY-ACQUIRED CEREBROSPINAL FLUID FOR DISEASE MONITORING
Riviere-Cazaux, Cécile , Mo, Wei , Dong, X, Warrington, A.P., Dong, X, Luo, Sheng , Wang, Andrew Zhuang , Du, P, Ghadimi, K, Warrington, A, Burns, Terry C.

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii106-ii107

10.1093/neuonc/noad137.358 Get It

Abstract BACKGROUND Few methods exist via which to assess treatment response with high fidelity in gliomas. Cell-free DNA (cfDNA) is of growing interest as a liquid biomarker in plasma and CSF and has been used in other cancer types to optimize therapeutic regimens for individual patients. While CSF has previously been used as a source of cfDNA for gliomas, it remains unknown how cfDNA abundance and sequencing change throughout treatment and inevitable recurrence. To that end, we leveraged our growing biobank of longitudinal CSF specimens, acquired via CSF access devices, to determine the potential utility of CSF cfDNA as a monitoring tool for treatment response in patients with gliomas. MATERIAL AND METHODS Longitudinal CSF specimens were acquired via Ommaya reservoirs (NCT04692337) or ventriculoperitoneal shunts (NCT04692324) in patients with brain tumors, including gliomas. cfDNA was extracted from 1-5 mL of CSF based on available sample volumes and quantified via Qubit. Next-Generation sequencing (PredicineCARE) or low-pass whole genome sequencing (LPWGS) was performed by Predicine, Inc based on the amount of cfDNA available. RESULTS CSF acquired prior to versus after resection demonstrated an increase in quantified cfDNA (2.97x, range: 1.58-5.26x), consistent with the impact of increased parenchymal disruption and closer contact with CSF. Thereafter, CSF cfDNA continued to decrease throughout chemoradiation and adjuvant treatment and increased at recurrence, including in patients co-enrolled in immunotherapy trials for IL-7 agonists and pembrolizumab. Interestingly, copy number burden (CNB) increased by the time of recurrence in three patients with known disease progression, and continued to decrease throughout immunotherapy treatment in one patient despite concerns of pseudoprogression. In one patient with a hypermutated glioblastoma, CSF cfDNA revealed over 59 genomic alterations, including MAP2K1, KIT, and PDGFRA, and over 100 more variants of unknown significance, each of which had been detected in sequencing of the tissue acquired at resection and subsequently decreased with chemoradiation. In another patient with a known progressing EGFR-amplified GBM, over 200 new variants were identified by the patient’s final sample and EGFR copy number increased from 2 to over 30. CONCLUSION Analysis of cfDNA over a patient’s disease course, including resection and treatment with standard-of-care and experimental therapies, may be of use for disease monitoring and treatment response. Further work is needed to evaluate these findings in a larger cohort of patients and to determine the sensitivity of changes in mutations, CNB, and cfDNA quantity for glioma disease burden.
The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories
Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Compton, Kelly, Xu, Rixing, Mishra, Rashmi , Drangsholt, Mark, Antunes, José Leopoldo Ferreira , Acheson, Alistair, Lu, Dan , Wallace, Lindsey E., Kocarnik, Jonathan , Fu, Weijia , Dean, Frances , Pennini, Alyssa, Henrikson, Hannah , Alam, Shazia , Ababneh, Emad , Abdoun, Meriem , Abidi, Hassan , Ali, Hiwa Abubaker, Adane, Tigist Demssew , Ahmad, Aqeel , Rashid, Tarik A. , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Aravkin, Aleksandr Y. , Aruleba, Raphael Taiwo , Azadnajafabad, Sina , Azangou‐Khyavy, Mohammadreza , Badar, Muhammad , Barqawi, Hiba Jawdat , Bashir, Nasir Zeeshan , Bashiri, Azadeh, Benzian, Habib , Bhagat, Devidas S. , Bhojaraja, Vijayalakshmi S, Bouaoud, Souad, Braithwaite, Dejana , Брико, Н. И. , Chakraborty, Promit Ananyo , Chattu, Vijay Kumar , Chaurasia, Akhilanand , Chen, Mengxuan , Cho, William C. , Chu, Dinh‐Toi , Chukwu, Isaac Sunday , Chung, Eunice, Martins, Natália , Dadras, Omid , Dandona, Lalit , Dandona, Rakhi , Daneshpajouhnejad, Parnaz , Molla, Meseret Derbew , Dessalegn, Fikadu Nugusu, Digesa, Lankamo Ena , Dixit, Shilpi Gupta , Dixit, Abhinav , Djalalinia, Shirin , Tantawi, Maha El , Enyew, Daniel Berhanie, Erku, Daniel , Ezzeddini, Rana, Fagbamigbe, Adeniyi Francis , Falzone, Luca , Fetensa, Getahun, Fukumoto, Takeshi , Gebrehiwot, Mesfin , Ghashghaee, Ahmad , Golechha, Mahaveer , Goleij, Pouya , Gorini, Giuseppe , Guimarães, André Luiz Sena , Gupta, Sapna , Halboub, Esam , Hanif, Asif , Harorani, Mehdi , Hasani, Hamidreza, Hassan, Abbas M. , Hassen, Mohammed Bheser, Hay, Simon I , Herrera-Serna, Brenda Yuliana , Hosseinzadeh, Mehdi , Ilić, Irena , Isola, Gaetano , Jaiswal, Abhishek , Jani, Chinmay , Javaheri, Tahereh , Jayaram, Shubha, Joseph, Nitin , Kadashetti, Vidya, Karanth, Shama D. , Kaur, Harkiran , Keykhaei, Mohammad , Khader, Yousef , Khajuria, Himanshu , Khanali, Javad , Khatib, Mahalaqua Nazli , Kashani, Hamid Reza Khayat , Kim, Min Seo , Kompani, Farzad , Kurmi, Om , Lal, Dharmesh Kumar, Lee, Yo Han , Lim, Stephen S , Listl, Stefan , Lopukhov, Platon D , Mafi, Ahmad R , Malik, Ahmad Azam , Maulud, Sazan Qadir , Nasab, Entezar Mehrabi, Mirfakhraie, Reza , Misganaw, Awoke, Misra, Sanjeev , Mithra, Prasanna , Mohammad, Yousef , Moni, Mohammad Ali , Moraga, Paula , Mubarik, Sumaira , Murray, Christopher J L , Swamy, Sreenivas Narasimha, Narayana, Aparna Ichalangod, Nassereldine, Hasan , Natto, Zuhair S. , Nayak, Biswa Prakash , Negru, Șerban , Nggada, Haruna Asura , Núñez-Samudio, Virginia , Oancea, Bogdan , Padrón‐Monedero, Alicia , Pandey, Anamika , Patel, Jay , Pezzani, Raffaele , Piracha, Zahra Zahid , Rabiee, Navid , Radhakrishnan, Venkatraman , Rahmani, Amir M. , Rao, Sowmya J, Rath, Goura Kishor, Rawaf, David Laith , Rawassizadeh, Reza , Rezaei, Nazila, Rezapour, Aziz , Riad, Abanoub , Romero‐Rodríguez, Esperanza , Manjula, S, Chandan, S N , Saddik, Basema , Saeed, Umar , Safaei, Mohsen , Sahebazzamani, Maryam , Samy, Abdallah M , Santric-Milicevic, Milena M , Sathian, Brijesh , Satpathy, Maheswar , Šekerija, Mario , Senthilkumaran, Subramanian , Seylani, Allen, Shafaat, Omid , Sharew, Mequannent Melaku Sharew, Sharifi‐Rad, Javad , Shorofi, Seyed Afshin, Shrestha, Sunil , Malleshappa, Sudeep K Siddappa , Singh, Paramdeep , Sinha, Dhirendra Narain , Solomon, Yonatan , Suleman, Muhammad , Abdulkader, Rizwan Suliankatchi , Abkenar, Yasaman Taheri, Tan, Ker‐Kan , Tbakhi, Abdelghani, Thiyagarajan, Arulmani , Tovani‐Palone, Marcos Roberto , Volovăț, Simona Ruxandra , Westerman, Ronny, Wickramasinghe, Nuwan Darshana , Xiao, Hong , Zadnik, Vesna, Zare, Iman, Zhang, Zhi-Jiang , Force, Lisa M , Hugo, Fernando Neves , Hoogar, Praveen , Rezaei, Nazila , Rezaei, Nazila , Shivakumar, KM , Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Cunha, Amanda Ramos da , Kerr, Alexander Ross , Wallace, Lindsey E., Abd‐Elsalam, Sherief , Abu‐Gharbieh, Eman , Addo, Isaac Yeboah , Ahmad, Sajjad , Akonde, Maxwell , Al‐Maweri, Sadeq Ali , Alsharif, Ubai , Ansari‐Moghaddam, Alireza , Anwar, Sumadi Lukman, Arabloo, Jalal , Asaad, Malke, Ashraf, Tahira , Athari, Seyyed Shamsadin , Attia, Sameh , Baghcheghi, Nayereh , Banach, Maciej , Bardhan, Mainak , Bernabé, Eduardo , Bjørge, Tone , Călina, Daniela Cornelia , Carreras, Giulia , Dai, Xiaochen , Soltani, Reza Darvishi Cheshmeh , Darwesh, Aso Mohammad , Debela, Sisay Abebe , Dianatinasab, Mostafa , Sayed, Iman El , Gaewkhiew, Piyada , Gallus, Silvano , Gill, Paramjit Singh , Gomez, Ricardo Santiago , Gupta, Bhawna , Gupta, Veer Bala , Gupta, Vivek , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hariyani, Ninuk , Hassanipour, Soheil , Hayat, Khezar , Holla, Ramesh , Horita, Nobuyuki , Hussain, Salman , Ilesanmi, Olayinka Stephen , Ilić, Milena , Jayarajah, Umesh , Kandaswamy, Eswar , Karaye, Ibraheem M. , Kauppila, Joonas H. , Tabari, Mohammad Amin Khazeei , Koohestani, Hamid Reza , Kumar, G Anil , Vecchia, Carlo La , Lal, Dharmesh Kumar, Landires, Iván , Lasrado, Savita , Ledda, Caterina , Libra, Massimo , Mahumud, Rashidul Alam , Mathur, Manu Raj , Meena, Jitendra Kumar , Meštrović, Tomislav , Mohammadi, Mokhtar, Mohammadi, Esmaeil , Mokdad, Ali H. , Morrison, Shane D. , Mozaffari, Hamid Reza , Nair, Tapas Sadasivan , Nouraei, Hasti , Olagunju, Andrew T , Bali, Ahmed Omar , Padubidri, Jagadish Rao , Pardhan, Shahina , Radhakrishnan, Raghu , Rahmani, Amir Masoud, Rahmanian, Vahid , Rao, Chythra R , Rawaf, Salman , Razeghinia, Mohammad Sadegh , Rezaei, Negar , Rezaei, Nima , Rezapour, Aziz , Roberts, Thomas J. , Roshandel, Gholamreza , Saeb, Mohammad Reza , Sahebkar, Amirhossein , Farrokhi, Amir Salek , Shahsavari, Hamid R. , Shamsoddin, Erfan , Shetty, Jeevan K. , Shivakumar, K. M. , Shobeiri, Parnian , Singh, Jasvinder A. , Singh, Garima Prateek , Talaat, Iman Mamdouh , Tiyuri, Amir , Unnikrishnan, Bhaskaran , Vo, Bay, Wang, Cong , Yu, Chuanhua , Yüce, Deniz , Yunusa, Ismaeel , Zoladl, Mohammad , Alahdab, Fares

Mayo Clinic

JAMA Oncology | September 7, 2023 | Volume: 9 | Issue: 10 | Pages: 1401

10.1001/jamaoncol.2023.2960 | PMID 37676656 Get It

ImportanceLip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning.ObjectiveTo analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates.Evidence ReviewThe incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019.FindingsIn 2019, 370 000 (95% uncertainty interval [UI], 338 000-401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000-180 000) cases and 114 000 (95% UI, 103 000-126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0-6.0 million) and 3.2 million (95% UI, 2.9-3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%-62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%-21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%-48.6%] and 40.2% [95% UI, 33.3%-46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%-33.8%]), driven by high risk-attributable burden in South and Southeast Asia.Conclusions and RelevanceIn this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts.
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study
Battat, Robert , Pai, Rish K. , Wang, Zhongya , Zou, Guangyong , McDonald, John WD, Duijvestein, Marjolijn , Jeyarajah, Jenny , Parker, Claire E. , Viegen, Tanja van, Nelson, Sigrid, Boland, Brigid S. , Singh, Siddharth , Dulai, Parambir S. , Feagan, Brian G. , Sandborn, William J. , Pai, R K , Jeyarajah, Jenny , Parker, Claire E , Singh, S , Dulai, Parambir S , Feagan, B G , Jairath, V , Sandborn, W J , Zou, Guangyong , Casteele, Niels Vande , Valasek, Mark A. , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 4, 2023 | Volume: 52 | Issue: 10 | Pages: 1574-1582

10.1111/apt.16083 | PMID 32981088 Get It

SummaryBackgroundThe optimal ulcerative colitis biopsy protocol is unclear.AimTo evaluate the number of biopsies required to accurately assess microscopic disease activity in ulcerative colitisMethodsBiopsies from patients with ≥4 rectosigmoid samples, and clinical and endoscopic data, were retrospectively obtained from a prospective biobank. Histology and endoscopic videos were read blindly. A 4‐biopsy Robarts Histopathology Index (RHI) reference score, consisting of the worst item‐level ratings from four biopsies, was compared to 1‐, 2‐ and 3‐biopsy estimates. Agreement was determined using bivariate errors‐in‐variable regression analysis (acceptance interval: ±8.25). Endoscopic activity and disease location subgroup analyses were also performed.ResultsForty‐six patients had ≥4 rectosigmoid biopsies available (N = 287). The 2‐biopsy (tolerance interval: −7.66, 4.79) and 3‐biopsy (tolerance interval: −4.86, 3.46) RHI scores demonstrated acceptable agreement with 4‐biopsy scores. One‐biopsy scores demonstrated unacceptable agreement (tolerance interval: −13.99, 7.78). Mean RHI scores using the 2‐, 3‐ and 4‐biopsy approaches were similar (6.1 ± 9.6 P = 0.36; 6.8 ± 10.5, P = 0.7; 7.5 ± 11.2), whereas the 1‐biopsy estimate was lower (4.4 ± 8.1, P = 0.06). Histological remission rates were identical for the 2‐, 3‐ and 4‐biopsy methods (65.2%, P = 1.0). Subgroup analysis demonstrated that three biopsies were required in patients with endoscopically active disease. Sampling additional colonic locations yielded lower histological remission rates compared to rectosigmoid sampling alone (33.3% vs 61.9%, P = 0.1).ConclusionsA minimum of two — conservatively, three — biopsies are required to reliably assess disease activity in a single colonic segment using the RHI. Further studies are needed of endoscopically active patients and sampling locations. These results have implications for biopsy strategies in clinical trials and practice.
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Adappa, Nithin D. , Beswick, Daniel M. , London, Nyall R. , Su, Shirley Y. , Wang, Marilene B. , Alexiev, Borislav A. , Antognoni, Paolo , Alonso‐Basanta, Michelle , Batra, Pete S., Bhayani, Mihir K. , Bell, Diana , Betz, Christian , Callejas, Claudio , Casiano, Roy R. , Chatzinakis, Vasileios , Chen, Simon , Chowdhury, Naweed I. , Citardi, Martin J. , Cohen, Marc A. , Dagan, Roi , Dalfino, Gianluca , Dassi, Camila , Almeida, John R. de , Tos, Angelo Paolo Dei , DelGaudio, John M. , Ebert, Charles S. , Eloy, Jean Anderson , Evans, James J., Fang, Christina H. , Farrell, Nyssa Fox , Ferrari, Marco , Fischbein, Nancy J. , Folbe, Adam J. , Fox, Meha G. , Lund, Valerie J. , Gallia, Gary L. , Gardner, Paul A. , Getz, Anne E., Govindaraj, Satish, Gray, Stacey T. , Gross, Bradley A. , Guo, Ruifeng , Ha, Patrick K. , Halderman, Ashleigh A. , Hanna, Ehab Y., Harvey, Richard J. , Hernandez, Stephen, Hopkins, Claire , Huang, Zhigang , Huang, Zhenxiao , Humphreys, Ian M. , Hwang, Peter H. , Iloreta, Alfred Marc, Ishii, Masaru , Jafari, Aria , Kennedy, David W. , Khan, Mohemmed, Kimple, Adam J. , Kingdom, Todd T. , Knisely, Anna, Kuo, Ying‐Ju , Lamarre, Eric , Lan, Ming‐Ying , Le, Hien , Lee, Nancy Y. , Lee, Jivianne K., Lee, Victor , Levine, Corinna G. , Lin, Jin‐Ching , Lin, Derrick T., Locke, Tran B. , Luong, Amber , Magliocca, Kelly R. , Matnjani, G., Meço, Cem , Michel, Loren S. , Na'ara, Shorook, Nicolai, Piero , Nuss, Daniel W. , Nyquist, Gurston , Oakley, Gretchen M. , Omura, Kazuhiro , Orlandi, Richard R. , Otori, Nobuyoshi , Papagiannopoulos, Peter , Patel, Zara M. , Pfister, David G. , Rabinowitz, Mindy, Sanusi, Olabisi , Sargi, Zoukaa , Schafhausen, Philippe, Schlosser, Rodney J. , Sedaghat, Ahmad R. , Senior, Brent A. , Shrivastava, Raj , Sindwani, Raj , Smith, Timothy L. , Smith, Kristine A. , Solares, C. Arturo , Stamm, Aldo Cassol , Stölzel, Katharina , Sumer, Baran D. , Tajudeen, Bobby A. , Thorp, Brian D. , Tsang, Raymond K. , VanKoevering, Kyle K. , Welch, Kevin C. , Wise, Sarah K. , Witterick, Ian , Won, Tae‐Bin , Wong, Stéphanie , Woodworth, Bradford A. , Wormald, Peter‐John , Zhou, Bing , Adappa, Nithin D. , Chapurin, Nikita , Ayoub, Noel , Bitner, Benjamin F. , Chang, Michael T. , Kuan, Edward C , Wang, Eric W , Beswick, Daniel , Wang, Marilene B , Alt, Jeremiah A , Bleier, Benjamin , Callejas, Claudio , Choby, Garret , Dalfino, Gianluca , Eloy, Jean Anderson , Fang, Christina H , Farrell, Nyssa F , Ferrari, Marco , Georgalas, Christos , Grayson, Jessica W , Harvey, Richard J , Holtzman, Adam L. , Hopkins, Claire , Humphreys, Ian M , Hwang, Peter H , Jafari, Aria , Kimple, Adam J , Lal, Devyani , Lan, Ming-Ying , Luong, Amber U , Meço, Cem , Omura, Kazuhiro , Orlandi, Richard , Patel, Zara , Sedaghat, Ahmad R , Senior, Brent A , Smith, Timothy L , Smith, Kristine , Snyderman, Carl H , Tong, Charles C L , van Zele, Thibaut , Won, Tae-Bin , Woodworth, Bradford A , Yao, William C , Yeh, Chien-Fu , Zhou, Bing , Schlosser, Rodney J , Bitner, Benjamin , Guo, Ruifeng , Chang, Michael T , Su, Shirley Y , Locke, Tran Bao , Adappa, Nithin D. , Abuzeid, Waleed M. , Alt, Jeremiah A. , Bernal‐Sprekelsen, Manuel , Blay, Jean‐Yves , Bleier, Benjamin S. , Bonilla‐Velez, Juliana , Carrau, Ricardo L. , Castelnuovo, Paolo , Chandra, Rakesh Kumar , Chiu, Alexander G. , Choby, Garret , Dallan, Iacopo , El‐Sayed, Ivan H. , Fokkens, Wytske Johanna , Geltzeiler, Mathew , Grayson, Jessica W. , Gross, Bradley , Grube, Jordon G. , Hanna, Ehab Y., Ivan, Michael E , Khan, Mohemmed N., Lal, Devyani , Lechner, Matt , Lobo, Brian C. , Markovic, Svetomir N. , McKean, Erin L. , Mendenhall, William M , Phan, Jack , Psaltis, Alkis J. , Ramanathan, Murugappan , Rimmer, Ryan , Rosen, Marc R , Sreenath, Satyan B , Šurda, Pavol , Thompson, Lester D.�R. , Turner, Justin H. , Turri‐Zanoni, Mario , Udager, Aaron M , Yao, William C.

Mayo Clinic

International Forum of Allergy & Rhinology | September 2, 2023 | Volume: 14 | Issue: 2 | Pages: 149-608

10.1002/alr.23262 | PMID 37658764 Get It

Abstract Background Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field. Methods In accordance with prior International Consensus Statement on Allergy and Rhinology documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on the level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication. Results The ICSNT document consists of four major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention. Conclusion As an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.
Randomised study: effects of the 5‐HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis
Chedid, Victor , Brandler, Justin , Arndt, Kayla, Vijayvargiya, Priya , Burton, Duane, Harmsen, William S. , Siegelman, Jenifer , Chen, Chunlin , Chen, Yinzhong , Dukes, George E. , Camilleri, Michael , Camilleri, M , Chedid, Victor G , Wang, Xiao‐Jing , Almansa, Cristina

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 1, 2023 | Volume: 53 | Issue: 9 | Pages: 1010-1020

10.1111/apt.16304 | PMID 33711180 Get It

SummaryBackgroundGastroparesis is defined by delayed gastric emptying with associated symptoms in the absence of mechanical obstruction.AimTo evaluate pharmacokinetics and pharmacodynamics of felcisetrag, a highly selective 5‐HT4 receptor agonist, on total gut transit in patients with documented delayed gastric emptying of solids.MethodsSingle‐centre, placebo‐controlled study of 36 participants receiving placebo, 0.1mg, 0.3mg or 1.0mg of felcisetrag I.V. infusion, daily, for 3 days. At baseline, each participant completed a 4h, 99mTc‐egg meal (300 kcal, 30% fat) gastric emptying test. Following infusion (Day 2), gastric, small bowel and colonic transit of solids were measured over 48h (same meal plus 111In‐charcoal delivered in methacrylate‐coated capsule). Samples were collected for pharmacokinetics. The primary endpoint was gastric emptying T1/2. Statistical analysis used baseline parameters as covariates (ANCOVA).ResultsPatients (22 idiopathic, 14 diabetic gastroparesis) were randomised to felcisetrag (0.1 mg, n = 10; 0.3 mg, n = 9; 1.0 mg, n = 7) or placebo (n = 10). Compared to placebo, felcisetrag significantly accelerated gastric emptying T1/2, colonic filling at 6h, and 10% small bowel transit time (overall P < 0.01; all three doses individually Bonferroni corrected P < 0.05) for all three measurements. Ascending colon emptying (T1/2) was significantly accelerated (all doses), and colonic transit at 48 hours was accelerated with 0.1 mg and 0.3 mg felcisetrag compared to placebo. Pharmacokinetic results were dose proportional. Felcisetrag was well tolerated with no clinically significant findings from clinical laboratory, vital signs or ECG.ConclusionI.V. felcisetrag significantly accelerated gastric, small bowel and colonic transit in patients with gastroparesis, and should be further evaluated for short‐term treatment of gastric and intestinal motility disorders.ClinicalTrials.gov #NCT03281577